CN106344232A - Sustained release medicine bracket for nasal cavity, forming method and application thereof - Google Patents
Sustained release medicine bracket for nasal cavity, forming method and application thereof Download PDFInfo
- Publication number
- CN106344232A CN106344232A CN201510413080.8A CN201510413080A CN106344232A CN 106344232 A CN106344232 A CN 106344232A CN 201510413080 A CN201510413080 A CN 201510413080A CN 106344232 A CN106344232 A CN 106344232A
- Authority
- CN
- China
- Prior art keywords
- slow releasing
- releasing pharmaceutical
- tow
- main body
- nasal cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The invention relates to a sustained release medicine bracket for a nasal cavity. The sustained release medicine bracket for the nasal cavity comprises a main body and at least one bottom, wherein the main body is of a grid structure formed by interweaving silk yarns or tows with each other. The main body extends circumferentially and has tail ends relative to each other; the bottom protrudes outwardly in a curved-surface shape; the periphery of the bottom is aligned and connected with the edges of the tail ends; the main body and the bottom carry a medicine which can be sustainedly released for the treatment of nasosinusitis. The invention further discloses a method for forming the sustained release medicine bracket for the nasal cavity. According to the sustained release medicine bracket for the nasal cavity, the wall surface of the main body is used for the wall-attaching treatment of a wound surface, at the same time, the bottom is used to stretch into a concave pit of the disease sites for the wall-attaching treatment, so as to act on the inflammation in the concave pit, accordingly, mucosal inflammatory and edema are effectively relieved, mucosal healing is promoted, scar formation is reduced, and postoperative adhesions are eliminated.
Description
Technical field
The present invention relates to a kind of medical apparatus and instruments, particularly to a kind of slow releasing pharmaceutical support for nasal cavity and its
Forming method and application.
Background technology
Sinusitis and allergic rhinitises are otorhinolaryngology commonly encountered diseases and frequently-occurring disease, betide between 5～79 years old.Defend
Raw department investigation display: the sickness rate of global allergic rhinitises up to 10% to 14% at present, sinusitis are sent out
Sick rate accounts for the 15% about of population, and the whole world has nearly 600,000,000 people enduring to the fullest extent " harassing and wrecking " of rhinitis, and
It is in gradually rise trend.
Wherein 66% asthmatic patient is the victim of allergic rhinitises.According to expert introduction, allergic rhinitises
As correctly treated, the patient more than 1/3 finally develops into asthma.
In addition, the sickness rate of anosmia 30% is caused by chronic sinusitiss, respiratory olfactory sensation is caused to subtract
Move back or anodimia, olfactory sensation is that olfactorin reaches regio olfactoria mucosa with breathing or to nasal cavity injection air-flow, by olfactory cell
Impression reaches cortical center and produces.As nostril, nasal cavity or nasopharynx part locking or adhesion, middle nasal concha with
Concha nasalis inferior enlargement, nasal cavity chronic granuloma (caused by the specific infection such as tuberculosis, syphilis, leprosy or scleroma),
Caused by chronic sinusitiss, allergic rhinitis, nasal polyp or tumor and deviation of nasal septum etc., nasal obstruction, takes
Air-flow with olfactorin is obstructed in nasal cavity, you can hyposmia or disappearance.
Nasal sinuses, also known as paranasal sinusess, paranasal sinus, are the sclerotin chamber of multiple gassiness around nasal cavity, they are all with little
Pipe is communicated with nasal cavity.They hidden on nasal cavity side, maxillary sinus are located at nasal cavity both sides, upper above eye socket
In jawbone；Sinus frontalis is in frontal bone；Sieve hole is located at the both sides on nasal cavity top, by gassiness loculuses many in screen casing
Composition；Sphenoid sinus is talked endlessly in bone nasal cavity rear.
Epidermal mucosa cell in the nasal cavity of normal person and nasal sinuses persistently has limpid liquid secretion out, then
There is the pulsation of rule rate via the cilium above mucosa cells, by these secretions from nasal sinuses, past via nasal cavity
After flow to cavum nasopharyngeum, throat and swallow again in esophagus and stomach.General adult about secretes 1 liter daily
Mucus, to maintain the humidity within nasal cavity and nasal sinuses by these mucus, adsorbs the dust of in the air simultaneously
And foreign body, to protect the health of respiratory tract.Once because virus, the invasion of antibacterial, or the stimulation of foreign body,
Pus are thick to lead to limpid mucilage secretion to be changed into, or the pulsation having rule rate lost by cilium, all can produce pus thick
Nasal mucus or the sensation of nasal mucus refluence, and it is led to rhinitis or nose film swelling, all can make these tubular occultation.When
During these tubular occultation, just influence whether that nasal cavity mucus remains in a standstill in nasal sinuses, impact discharge.If too late
Early diagnosis and treatment, will develop and become sinusitis, allergic rhinitises or other rhinitis.
Headache, nasal obstruction, rhinorrhea, temporary olfactory disorder, fear of cold can be caused when nasal sinuses inflammation, send out
Heat, inappetence, constipation, whole body discomfort etc..Can vomit, suffer from diarrhoea, cough compared with small children child
Etc. symptom.Pus nasal mucus stimulates throat can also cause throat discomfort, pharyngolaryngitis etc..
And allergic rhinitises, usual patient contact or after sucking sensitinogen, internal ige (immunoglobulin
E) mastocyte release histamine can be led to, cause anaphylaxiss.Allergen is that inducing specific ige resists
Body the antigen reacting therewith.Their multi-sources are in animal, plant, insecticide, funguses or occupational
Material.Allergen is broadly divided into inhalant allergen and food-consuming structure.Inhalant allergen is allergic effect
The main cause of property rhinitis.The patient of allergic rhinitises is mainly shown as that telangiectasis, permeability increase
Plus and glandular secretion increase and eosinophilic granulocyte infiltration etc..If above-mentioned disease recurrent exerbation, can cause glutinous
Film epithelial layer propagation sexually revises, and leads to mucosa plump and Polypoid changes.Its symptom is similar to flu, mainly
It is the diseases such as rhinocnesmus, nasal obstruction, rhinorrhea, sneeze and stream clear water shape nasal mucus (runny nose), intermittence is sent out repeatedly
Make, nasal mucosa pale edema during outbreak.Seriously it is also possible to develop into sinusitis, asthma or ear's sense
Dye.
Endoscopy nasal surgery has become as main flow, has particularly apparent treatment to sinusitis
Effect.Pathological tissues and bone can accurately be removed, make nasal sinuses enlarged open, recover the normal of nasal sinuses
Physiological function.Findings in endoscopic sinus surgery has the incomparable invasive of traditional sinusitis operation, but art
The recovery of posterula nasal sinuses function needs the regular hour, and recovery effects are also because individual variation and rhinology are special
There is certain difference in the complexity reason such as impact of different pathophysiological mechanism, postoperative need the long period
The Drug therapy of (usual 2-3 month) and follow-up are processed.Another aspect nasal cavity space is narrow, and operation is disposed
Relatively difficult, and it is easily caused adhesion of nasal cavity, thus the related complication of secondary and recurrence are possible, it is nose
Endoscopic surgery improves difficulty.
Treatment allergic rhinitises operative therapy mainly have the treatment of nerve block art, low-temperature plasma art, under
The operation of concha nasalis mucosa, reduction parasympathetic nervouss irritability operation, and other operative therapy, above-mentioned operation
High recurrence rate, costly.
For application in nose diseasess for the Drug therapy, traditionally adopt collunarium or spray to nasal cavity
The mode of spraying medicine.Research shows, due to blocking of tissue, drug molecule under traditional therapeutic modality
Diseased region can not smoothly be reached, uneven for the medicinal liquid less than 30% can only be sent to diseased region,
Greatly reduce medication effect.
Have nasal cavity flushing device at present, normal saline or the medicine liquid washing nasal cavity containing medicine can be used,
But of short duration medicine effect is almost confined in concha nasalis position, can not reach in sinus frontalis and maxillary sinus hole body
Portion is it is impossible to inflammation nasal sinuses direct effect, and most nasal sinuses occur pathological changes can be related to nearly all hole body.
In fact, even if medicinal liquid can enter hole body cavity inside, and for sinus frontalis opening is in the hole body of bottom,
After the completion of cleaning or spray, nearly all medicinal liquid all can be flowed out by Dou Kou, and medicine also has no chance to store
Carry out permanently effective treatment inside it.
Drug releasing stent des (durg eluting stent) obtains in terms of coronary stricture disease
It is widely applied and approves, des support applies the medicine of promising treatment vascular restenosiss or anti-neointimal hyperplasia,
I.e. medication coat, can provide long-time slow release to supply according to design requirement for patient after implantation diseased region
Medicine.This slow release chemical supply machine manage for nasal cavity etc. other need for a long time uninterruptedly treatment disease provide new
Direction and foundation are although nasal sinuses stenostomy and angiostenosiss can lean on supporter (such as, support) to support
Open and reach unimpeded purpose, but because nasal cavity structure and blood circulation are from physiology and pathogenic mechanism
Upper have much differences, can not indiscriminately imitate des completely in terms of the long-term controlled release treatment of nasal cavity (in nasal sinuses)
The pattern of support.Blood circulation is closed-system, and Restenosis are to occur in a segment length
Narrow or even blocking, is coated in the effect of the medicine outside intravascular stent and only needs to cover or be diffused into pathological changes week
Enclose, and under enough blood flows wash away, the medicine in des bracket coating naturally can spread and carry
Bring good therapeutic effect to perilesional.For blood circulation, nasal cavity, including nose
Hole is all the cavity of opening, and the individual variation of nasal cavity structure is more much bigger than blood vessel difference.
Patent application cn101945621 discloses one kind from expanding unit, and it is by least polymer filament
The linear main body circumferentially extending, has ring, wherein, this main body at the valley of this main body or valley
Concrete form is conducive to support to deform when compressed, and the ring of valley or valley provides elasticity for support.
Patent application cn201210454911.2 discloses a kind of prosthesis system, and it forms week by degradable polymer
To the main body extending, the biodegradable fiber tow containing medicine is interspersed in body interior, wherein, this main body
Concrete form be conducive to the compand of support, and carry biodegradable fiber tow and the pathological changes of medicine
Location contacts carry out the treatment such as antiinflammatory.
But, the main body of the existing drug stent for nasal cavity is tubular support, and two end is
Free end, usual traverse enters in nasal meatus, and the wall using main body carries out adherent treatment to wound surface.But,
Tubular support is only applicable to the cylindric wall of nasal meatus, and interpersonal nasal cavity space and shape
Body is widely different, and operating room doctor is also not quite similar to the process of different pathological, therefore, is propped up with tubular
The effect to the adherent treatment of different sufferers for the frame, difference is larger.In addition, clinical discovery, the ill portion of nasal cavity
Position is conventionally formed with pit.Particularly in the presence of pit, existing drug stent cannot stretch into this pit
Inside carry out adherent, thus lead to inflammation in pit sustainable development and cannot treat, therefore, existing
Drug stent is often unsatisfactory to the therapeutic effect of sinusitis and allergic rhinitises.
Content of the invention
In order to solve the recessed of disease sites that cannot pointedly act on nasal cavity that above-mentioned prior art exists
The problem in hole, the present invention is intended to provide a kind of slow releasing pharmaceutical support for nasal cavity, for treating anaphylaxis
Rhinitis and/or sinusitis, and the disease such as asthma, anosmia.
The present invention provides a kind of slow releasing pharmaceutical support for nasal cavity, including respectively by silk thread or tow each other
Interweave and form main body and at least one bottom of network, described main body is circumferentially extending and has phase each other
To end, described bottom curved outwardly, the edge pair of the periphery of described bottom and described end
Neat joint, described main body and described bottom carry can be by slow release for treating the medicine of sinusitis.
Described main body has latching point, and described latching point is the u being arranged at silk thread or tow being fitted to each other
Shape groove.
The material of the silk thread of described drug stent or tow is non-degradable metal, or degradable metal, or
Non-degradable polymer, or degradable polymer, or the mixture of above-mentioned material.
Described slow releasing pharmaceutical support also includes the brace rod fitting in base profile.
The material of described brace rod is non-degradable metal, or degradable metal, or non-degradable polymer,
Or degradable polymer, or the mixture of above-mentioned material.
Described network includes triangular grid structures.
Described medicine is included in the inside of the material of silk thread or tow, and/or the material being coated in silk thread or tow
The outer surface of material, and/or be carried in the network between silk thread or tow.
It is filled with hemostatic material in the spill of described drug stent.
Described hemostatic material has hygroscopicity and from swollen rising property, thus slow releasing pharmaceutical support described in assisting in opening.
Described hemostatic material is degradable polymer.For example, it is possible to be sponge, gel etc..Described only
Blood material can be degraded at short notice, or exclusion；Have an advantage in that and complete to stop blooding, open slow releasing pharmaceutical
After the effect of support, fast degradation is excluded, and keeps channels open.
The present invention also provides a kind of forming method of the slow releasing pharmaceutical support for nasal cavity, described slow releasing pharmaceutical
Support passes through artificial or machine braided silk or tow, or is printed by material 3d, or passes through laser
Cutting material is formed.
Described slow releasing pharmaceutical metal rack passes through quenching and temper, thus forming target shape.
Described slow releasing pharmaceutical support through thermal finalization and cooling step, thus forming target shape.Particularly
Polymeric medicine support needs through thermal finalization and cooling step.
Described heat setting temperature is between material glass temperature and fusing point；Described chilling temperature is less than material
Material vitrification point.
The step that described slow releasing pharmaceutical support manually adjusts through patient.
Slow releasing pharmaceutical support for nasal cavity provided by the present invention is pasted to wound surface using the wall of main body
Wall is treated, and is stretched in the pit of disease sites using bottom simultaneously and carries out adherent treatment, thus acting on recessed
Inflammation in hole, effectively mitigates mucosal inflammation and edema, promotes mucosa healing, reduce cicatrization, disappear
Except tissue adhesion.In addition, any hole needing to be placed support of nasal cavity and nasal meatus all can be considered as
A kind of " hole ", because this space has at " bottom ", the slow releasing medicinal for nasal cavity provided by the present invention
Thing support stretches in " hole " by means of bottom, as much as possible contact wound surface treated, the suitability and
Effectiveness is preferably improved.
Brief description
Fig. 1 is the schematic perspective view of the slow releasing pharmaceutical support according to the first embodiment of the present invention；
Fig. 2 is the top view of the slow releasing pharmaceutical support according to the first embodiment of the present invention；
Fig. 3 is the top view of slow releasing pharmaceutical support according to the second embodiment of the present invention；
Fig. 4 is the top view of slow releasing pharmaceutical support according to the third embodiment of the invention；
Fig. 5 is the schematic perspective view of slow releasing pharmaceutical support according to the fourth embodiment of the invention；
Fig. 6 is the schematic perspective view of slow releasing pharmaceutical support according to the fifth embodiment of the invention；
Fig. 7 is the schematic perspective view of slow releasing pharmaceutical support according to the sixth embodiment of the invention；
Fig. 8 is the schematic diagram of the first latching point of the slow releasing pharmaceutical support according to the present invention；
Fig. 9 is the schematic diagram of the second latching point of the slow releasing pharmaceutical support according to the present invention；And
Figure 10 is the schematic diagram of the brace rod of the slow releasing pharmaceutical support according to the present invention.
Specific embodiment
Below in conjunction with the accompanying drawings, provide presently preferred embodiments of the present invention, and be described in detail.
Embodiment 1
Fig. 1 is the schematic perspective view of the slow releasing pharmaceutical support according to the first embodiment of the present invention, this slow release
Drug stent 1 includes being interlaced with one another by degradable silk thread or degradable tow respectively and forms the master of network
Body 11 and bottom 12, described main body 11 is circumferentially extending and has end 111,112 relative to each other, institute
State bottom 12 curved outwardly, the edge of the periphery of described bottom 12 121 and described end 112
Alignment.In fact, aforementioned body 11 and bottom 12 are artificial two parts dividing, not necessarily
This two parts is coupled together by the position shown in in figure, carry out herein division be in order to prior art in
The drug stent without bottom 12 make a distinction.In the present embodiment, main body 11 and bottom 12 are adopted
It is integrally formed by winding with weaving manner.It should be understood, of course, that forming main body 11 and bottom first respectively
Portion 12, it is also feasible for then being coupled together both by any optional mode.
In the present embodiment, the drug stent 1 ultimately forming is rendered as the bowl-shape of hollow out, the end of main body 11
End 111 is formed as free end, and the edge of this free end is rounded.It should be understood that the shape at this edge is simultaneously
It is not limited to circle, ellipse or tetragon etc. are all feasible.
In the present embodiment, drug stent 1 passes through artificial or machine braiding degradable silk thread or degradable silk
Bundle is formed, and the material of this degradable silk thread or degradable tow adopts plga, and in copolymer, la accounting is
The accounting of 0% to 95%, ga is 5% to 100%, filament diameter 0.1mm-0.8mm.In weaving
Afterwards, drug stent 1 is ultimately formed by heat setting process, this thermal finalization is under fixed length anxiety heat set conditions
Carry out, 150-215 DEG C of setting temperature, shaping time 2-30min.
The steroidal anti-inflammatory drug thing slow release layer of spraying is had on drug stent 1 it is adaptable to the class of the present embodiment
Steroidal anti-inflammatory drug thing includes but is not limited to, 21- acetyl oxygen pregnenolone, alclometasone, algestone,
Amcinonide, beclometasone, betamethasone, budesonide, chloroprednisone, clobetasol, chlorine times he
Pine, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, rope how
Moral, desoximetasone, dexamethasone, diflorasone, diflucortolone, two fuprednate butyl esters, enoxolone,
Fluazacort, flucloronide, flumetasone, good fortune Buddhist nun shrinkage porosite, fluocinonide, fluocinonide, actuss fourth
Ester, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, good fortune prednisolone, flurandrenolide,
Fluticasone propionate, formocortal, halcinonide, Halobetasol Propionate, halometasone, acetic acid halogen sprinkle
Buddhist nun pine, hydrocortamate, hydrocortisone, Loteprednol etabonate, depersolon, medrysone, first are sprinkled
Buddhist nun pine, methyl meticortelone, Mo Meitasong furoate, paramethasone, prednicarbate, prednisolone,
25- diethylin prednisolone acetate, Inflamase, prednisone, prednival, ripple
Prednylidene 21-diethylaminoacetatte, rimexolone, tixocortol, triamcinolone, Triamcinolone Acetonide, triamcinolone benetonide, fluorine hydroxyl hydrogen
Change prednisone, triamcinolone hexacetonide, and its derivant and compositionss.
As shown in Fig. 2 the network of main body and bottom includes triangle 13, tetragon 14 or polygon
Shape 15.It is found through experiments, triangle 13 therein ensures support force and the dimensional stability of support, when
When this drug stent needs implantation opening larger position, in this drug stent, generally introduce multiple triangles
Shape, and tetragon 14 or polygon 15 provide deformation and elasticity for support, thus providing compression
May, facilitate support to be transported to nasal cavity.In fact, there is presently no any for nasal cavity can
Triangular grid structures are incorporated in support degraded slow releasing pharmaceutical support, and the present invention is creatively by triangle
Shape network and tetragon or polygonal mesh structure coordinated, thus provide can compression,
It is provided that the support of suitable support force, thus being applied to the different parts of nasal cavity to improve therapeutic effect again.
The drug stent 1 of the present embodiment is particularly well-suited to the positions such as middles nasal meatus, superior nasal meatuss, inferior nasal meatuss,
In actual application, the present invention carries out adherent treatment using the wall of main body 11 to wound surface, utilizes simultaneously
Outwardly (swell) bottom 12 and stretch in the pit of disease sites and carry out adherent treatment, thus acting on
Inflammation in pit, effectively mitigates mucosal inflammation and edema, promotes mucosa healing, minimizing cicatrization,
Eliminate tissue adhesion.
Especially, this drug stent 1 can fill hemostasis by means of bottom 12 in the matrix of drug stent
Material, such as styptic cotton, thus reduce postoperative hemorrhage symptom.In fact, inside existing drug stent
If filling styptic cotton, support will be applied with the active force of circumference, cause support intersection point cracking so as to lose
Lose enabling capabilities.
Embodiment 2
Fig. 3 is the schematic perspective view of degradable controlled release drug stent according to the second embodiment of the present invention,
This degradable controlled release drug stent 2 equally includes being interlaced with one another by degradable silk thread or degradable tow respectively
Form main body and the bottom of network, its same or similar detail of first embodiment with Fig. 1
Will not be described here.Unlike it, the main body of this drug stent 2 and the network of bottom do not include
Triangular structure, only has tetragon 24 or polygon 25.So, the drug stent 2 of the present embodiment is more
Easily by compression to less profile, support is facilitated to be delivered to narrower and small space.Especially, should
Drug stent 2 is applied to the positions such as middles nasal meatus, superior nasal meatuss, inferior nasal meatuss it is also possible to put into the hole body such as sinus frontalis
Internal.
Embodiment 3
Fig. 4 is the schematic perspective view of degradable controlled release drug stent according to the third embodiment of the invention,
This degradable controlled release drug stent 3 equally includes being interlaced with one another by degradable silk thread or degradable tow respectively
Form main body and the bottom of network, wherein, the network of bottom includes triangular structure 33,
Ensure the support force of support and dimensional stability it is adaptable to the larger position implantation of opening, the grid of main body
Structure includes quadrilateral structure 34, facilitates support to be delivered to nasal cavity, other first embodiment phases with Fig. 1
Same or similar detail will not be described here unlike it, except for the difference that, the medicine of the present embodiment
The material of the main body of support 3 is less, ensures less pressure while not reducing support support performance as far as possible
Contracting profile.Especially, this drug stent 3 is applied to the positions such as middles nasal meatus, superior nasal meatuss, inferior nasal meatuss.
Embodiment 4
Fig. 5 is the schematic perspective view of degradable controlled release drug stent according to the fourth embodiment of the invention,
This degradable controlled release drug stent 4 equally includes being interlaced with one another by degradable silk thread or degradable tow respectively
Form main body and the bottom of network, its same or similar detail of first embodiment with Fig. 1
Will not be described here.Unlike it, the material of this degradable silk thread or degradable tow adopts ppdo,
Filament diameter 0.2-1.0mm, monofilament can also be a kind of rectangle, trapezoidal or triangular-section.In weaver
After skill, drug stent 4 is ultimately formed by heat setting process, this thermal finalization is in fixed length anxiety heat set conditions
Under carry out, 30-80 DEG C of setting temperature, shaping time 3-30min.
In addition, there is nonsteroidal anti-inflammatory slow release layer on drug stent 4, can be used for the present embodiment
Nonsteroidal anti-inflammatory agent include but is not limited to, epoxidase (cox) inhibitor.This kind of epoxy
Enzyme (cox) inhibitor potentially includes cox-1 or cox nonspecific inhibitor, for example, salicylic acid
Derivant, aspirin, sodium salicylate, Choline magnesium trisalicylate, salsalate, diflunisal, willow
Nitrogen sulfapyridine, olsalazine；P-aminophenol derivatives, for example, acetaminophen；Indole and
Indeneacetic acid, for example, indomethacin and sulindac；Iso-aryl acetic acid class, for example, tolmetin,
Diclofenac, ketorolac；Arylprop acids, for example, ibuprofen, naproxen, Flurbiprofen, ketone group
Ibuprofen, Fino ibuprofen, oxaprozin；Anthranilic acid (fragrant that acid), for example, cresol that
Acid, Meloxicam；Enol acid, for example, former times health class (Piroxicam, Meloxicam)；Aldoketoneses,
For example, nabumetone.Cox inhibitor may also include selectivity cyclooxygenase cox2, for example, two
Aryl substituted furan ketone, rofecoxib；Diaryl substituted pyrazole class, Celecoxib；Heteroauxing class,
As Etodolac；Sulfonamidess, e.g., nimesulide.
The drug stent 4 ultimately forming of the present embodiment is rendered as the truncated conelike of hollow out, bottom slight of stature and
Main body is gradually widened.Therefore, this drug stent 4 is easy to fill in the entrance of hole, is particularly well-suited to vertical
Entrance, so that support is relatively fixed after filling in and be not easy to take off in the hole.
This support is applied to this support for the position such as sinus frontalis, sphenoethmoidal recess.When this support uses in art,
The vertex of a cone upward, into sinus frontalis or at sphenoethmoidal recess, can fill hemostatic material in it.
The drug stent 4 of the present embodiment is particularly well-suited to the positions such as sinus frontalis, sphenoethmoidal recess, in practical application
During, bottom-up, gradually into sinus frontalis or close at sphenoethmoidal recess, until being finally resisted against sinus frontalis
At interior or sphenoethmoidal recess.
Embodiment 5
Fig. 6 is the schematic perspective view of degradable controlled release drug stent according to the fifth embodiment of the invention,
This degradable controlled release drug stent 5 includes being interlaced with one another and being formed by degradable silk thread or degradable tow respectively
The main body 51 of network and two bottoms 52,53, described main body 51 is circumferentially extending and has phase each other
To end 511,512, described bottom 52,53 curved outwardly, described bottom 52,53
Periphery 521,531 and the justified margin of described end 511,512.In fact, aforementioned body 51 and bottom
Portion 52,53 is artificial two parts dividing, and the position shown in not necessarily in figure is by this two parts
Couple together, carry out division is to prop up with the medicine without bottom 52,53 of the prior art herein
Frame makes a distinction.In the present embodiment, main body 51 and bottom 52,53 are passed through 3d printing type one and are become
Type.It should be understood, of course, that forming main body 51 and bottom 52,53 first respectively, then pass through any can
Both are coupled together by the mode of choosing is also feasible.
In the present embodiment, the drug stent 5 ultimately forming is rendered as the hollow ball-shape of hollow out, and this is spherical
The support force providing is often very big, gives support enough elasticity to reduce support force, this medicine props up
The network of frame only includes tetragon in the present embodiment.It should be understood that its shape is not limited to
Spheroidal, elliposoidal or egg type etc. are all feasible.
In the present embodiment, drug stent 5 is by the way of degradable polymer 3d prints degradable tow
Formed, the material of this degradable tow adopts pgs, do not carry out thermal finalization and cooling treatment.Pgs conduct
Degradable polymer elastomer, possesses shape variability in itself under room temperature, elasticity is good, so that finally
The drug stent 5 being formed can carry out moulding.
Haemostatic medicament coating is had on drug stent 5, the haemostatic medicament that can be used for the present embodiment include but
It is not limited to, hemocoagulase, Desmopressin, vitamin k 1, vitamin k 3, vitamin k 4, vinegar are sweet
Propylhomoserin ethylenediamine, carbazochrome, carbazochrome sodium sulfonate, aminocaproic acid, aminomethylbenzoic acid, tranexamic acid, suppression peptide
Enzyme, human fibrinogen, thrombin, rutosids, pituitrin.
The drug stent 5 of the present embodiment is particularly well-suited to the positions such as sinus frontalis, sphenoethmoidal recess, in practical application
During, one of bottom-up, gradually into sinus frontalis or close at sphenoethmoidal recess, until finally supporting
Lean against in sinus frontalis or at sphenoethmoidal recess.
Embodiment 6
Fig. 7 is the schematic perspective view of degradable controlled release drug stent according to the sixth embodiment of the invention,
This degradable controlled release drug stent 6 equally includes being interlaced with one another by degradable silk thread or degradable tow respectively
The main body of formation network and two bottoms, same or similar specifically thin with the 5th embodiment of Fig. 6
Section will not be described here unlike it, and except for the difference that, the drug stent 6 of the present embodiment is rendered as hollow out
Hollow American football shape, in order to strengthen the support force radially along long axis direction, this drug stent 6
There is helical structure 61, to prevent this drug stent 6 from being flattened easily.
The drug stent 6 of the present embodiment such as is particularly well-suited at each nasal meatus and sphenoethmoidal recess at the position, in reality
In application process, one of bottom-up, gradually close at nasal meatus and sphenoethmoidal recess, until final
It is resisted against in sinus frontalis or at sphenoethmoidal recess.
The material of the degradable polymer silk thread in above-described embodiment or degradable polymer tow comprise but not
It is only limitted to following degradable polymer: polylactic acid (polylactic acid, pla), l- polylactic acid (polyllactic
Acid, plla or lpla), polyglycolic acid/copolymer of poly lactic acid (polyglycolic acid/polylactic
Acid, pgla), polycaprolactone (polycaprolactone, pcl), polyhydroxybutyrate valerate
(polyhydroxylbutyrate valerate, phbv), polyacetylglutamic acid (polyacetylglutamicacid,
Paga), polyorthoesters (polyorthoesters, poe) and polyethylene glycol oxide/polybutene copolymer
(polyethylene oxide/polybutylene terephthalate, peo/pbtp), PPDO
(poly-p-dioxanone, ppdo), poly butylene succinate (poly (butylene succinate),
Pbs), poly- decanedioic acid glyceride (poly (glycerol sebacate), pgs), shitosan, pva, and
The copolymer of above-mentioned material or blend, and its homologue.The medicine being ultimately formed by degradable polymer
Support can be degraded after placing a period of time automatically, need not take out.
The material of the non-degradable silk thread in above-described embodiment or non-degradable tow comprise but be not limited only to as
Lower polymer: polyethylene terephthalate (polyethylene terephthalate, pet), poly- to benzene two
Formic acid propylene glycol ester (polytrimethylene terephthalate, ptt), polybutylene terephthalate (PBT)
(polybutylene terephthalate, pbt), polyether-ether-ketone (polyetheretherketone, peek),
Acrylonitrile-butadiene-styrene copolymer (acrylonitrile-butadiene-styrene, abs), polytetrafluoro
Ethylene (polytetrafluoroethylene, ptfe), fluorinated ethylene propylene copolymer (fluorinated ethylene
Propylene, fep), polyamide (polyamide, pa), polystyrene (polystyrene, ps),
Polymethyl methacrylate (polymethyl methacrylate, pmma), polypropylene (polyprolene, pp),
Polyethylene (polyethylene, pe), polyformaldehyde (polyformaldehyde, pom), Merlon
(polycarbonate, pc), PAEK (polyetherketoneketone, paek), natural rubber, silicon
Glue, and the copolymer of above-mentioned material or blend, and its homologue.By non-degradable polymer end form
The drug stent becoming can not be degraded after placing a period of time automatically, need to be taken out by surgical.
The material of the degradable metal silk thread in above-described embodiment or metal degradable tow comprises but not only limits
In following degradable metal: magnesium and magnesium based alloys, ferrum and ferrous alloy, zinc and zinc-containing alloy, tungsten, (calcium
Base, zinc-base and strontio) non-crystaline amorphous metal.The drug stent being ultimately formed by degradable metal is placing one section
Can automatically degrade after time, need not take out.
The material of the non-degradable tinsel in above-described embodiment or metal non-degradable tow comprise but not
Be only limitted to following non-degradable metal: rustless steel, cobalt-base alloyss, titanium-base alloy, noble metal (gold, silver,
Platinum), tantalum, niobium, chromium, zirconium, marmem (niti-shaped memorial alloy, copper-base shape memory
Alloy).The drug stent being ultimately formed by non-degradable metal can not be automatic after placing a period of time
Degraded, need to be taken out by surgical.
Drug stent in above-described embodiment, carry can by slow release for treat nose diseasess (such as:
Sinusitis, allergic rhinitises, asthma, anosmia etc.) medicine, thus by medicament slow release play control
Treatment acts on, and can avoid or reduce the use of oral drugs during implanting.This medicine may be embodied in
State the inside of the material of the silk thread in embodiment or tow it is also possible to coat silk thread in the above-described embodiments
Or the outer surface of the material of tow, formation can controlled-release coating, can also be carried between silk thread or tow
In network.This can comprise the controlled degradable polymer of slow release and active drug by controlled-release coating, and coating can
To discharge one or more medicine, or the medicine of different deenergized period.
The controlled degradable polymer of above-mentioned slow release includes but is not limited to shitosan, Algin, cellulose
(l- tyrosine spreads out for ester, glucosan, elastin laminin, fibrin, hyaluronic acid, polyacetals, polyarylate
Biological or fatty acid), poly- α hydroxy ester, poly- β hydroxy ester, pva, peg, polyamide, poly- ammonia
Base acid, polyalkanoate, polyalkylene compound, polyethoxylate, polyalkylene succinic acid, polyacids
Acid anhydride, condensing model ester, poly-aspartate, poly butylene succinate, polycaprolactone, polycaprolactone/poly- second
Ethylene terephthalate copolymers, Merlon, l- tyrosine derived polycarbonates, polycyanoacrylate, poly- two
Hydrogen pyrans, PPDO, poly- 6-caprolactone, poly- 6-caprolactone-dimethyltrimethylene carbonic acid
Ester, polyesteramide, polyester, aliphatic polyester, polyether ester, Polyethylene Glycol/poe copolymer, poly-
1,3-propanedicarboxylic acid, polyglycolic acid, PGA, PGA/polyglycol ester interpolymer, PGA-Sanya
Methyl carbonic, polyhydroxyalkanoate, poly butyric ester, PHBV, poly- imido
Base carbonic ester, polyketals, Poly-L-lactic acid, Poly-L-lactic acid-glycolic, Poly-L-lactic acid-glycolic/
Ethylene glycol copolymer, poly- l lactide, poly- l lactide caprolactone, poly- dl lactide glycolide,
Poly- l lactide glycolide/polyglycol ester interpolymer, poly- l lactide/ethylene glycol copolymer, poly- l
Lactide/PGA copolymer, poe, polyoxyethylene/polyoxypropylene copolymer, polypeptide, poly- phosphorus
Nitrile, poly phosphate, APP ester, polypropylene fumaric acid ethylene glycol, PTMC, poly-
Tyrosine carbonic ester, polyurethane, fimbrin, spider silk, tephaflex, (Acetic acid, hydroxy-, bimol. cyclic ester,
Lactide and neopentyl glycol carbonic ester) terpolymer, viscose glue, cellulose, cellulose acetate, butyl ester
Cellulose, butyl acetate cellulose, cellophane, celluloid, cellulose propionate, cellulose ether,
Carboxymethyl cellulose, and the combination of above-mentioned polymer, mixture or copolymer.
Above-mentioned medicine may be selected from but not limited to following medicine: long-acting steroids hormone, anti-inflammatory agent,
Antiallergic agent, parasympatholytic, antihistaminic medicine, anti-infective, antiplatelet drug, hemostasis
Medicine, antithrombotic, anti-cicatrix medicine, cytostatics and anti-cell proliferation medicine, chemotherapy and antineoplastic agent,
The congested agent of solution, accelerator for concrescence, vitamin (such as: tretinoin, vitamin a, vitamin b, and its
Spin-off), immuno modulating agent, immunosuppressant, and the compositionss of above-mentioned medicament or mixture.
Preferably, optional anti-inflammatory agent generally includes steroid or nonsteroid anti-inflammatory drugses.
The steroidal antiinflammatory drug that can be used for the present invention includes but is not limited to, 21- acetyl oxygen pregnenolone,
Alclometasone, algestone, amcinonide, beclometasone, betamethasone, budesonide, chlorine sprinkle Buddhist nun
Pine, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, can cut down
Azoles, deflazacort, (11BETA,16ALPHA)-16,17-[methylethylidenebis(oxy), desoximetasone, dexamethasone, diflorasone, diflucortolone, two
Fuprednate butyl ester, enoxolone, Fluazacort, flucloronide, flumetasone, good fortune Buddhist nun shrinkage porosite, fluocinonide,
Fluocinonide, Novoderm Varlane, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate,
Good fortune prednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, Buprofein propanoic acid
Ester, halometasone, halopredone acetate, hydrocortamate, hydrocortisone, Loteprednol etabonate, first piperazine
Ground by force dragon, medrysone, meprednisone, methyl meticortelone, Mo Meitasong furoate, paramethasone,
Prednicarbate, prednisolone, 25- diethylin prednisolone acetate, Inflamase, prednisone,
Prednival, ripple prednylidene 21-diethylaminoacetatte, rimexolone, tixocortol, triamcinolone, Triamcinolone Acetonide,
Triamcinolone benetonide, Triamcinolone, triamcinolone hexacetonide, and its derivant and compositionss.
The nonsteroid anti-inflammatory drugses that can be used for the present invention include but is not limited to, and epoxidase (cox) suppresses
Agent.This kind of epoxidase (cox) inhibitor potentially includes cox-1 or cox nonspecific inhibitor, example
As, salicyclic acid derivatives, aspirin, sodium salicylate, Choline magnesium trisalicylate, salsalate, two
Fluorine Buddhist nun willow, sulfasalazine, olsalazine；P-aminophenol derivatives, for example, acetparaminosalol
Phenol；Indole and indeneacetic acid, for example, indomethacin and sulindac；Iso-aryl acetic acid class, for example, toluene
Acyl pyridylacetic acid, diclofenac, ketorolac；Arylprop acids, for example, ibuprofen, naproxen, fluorine
Than ibuprofen, ketone ibuprofen, Fino ibuprofen, oxaprozin；Anthranilic acid (that acid fragrant),
For example, mefenamic acid, Meloxicam；Enol acid, for example, former times health class (Piroxicam, U.S. Lip river former times
Health)；Aldoketoneses, for example, nabumetone.Cox inhibitor may also include selectivity cyclooxygenase cox2,
For example, diaryl substituted furan ketone, rofecoxib；Diaryl substituted pyrazole class, Celecoxib；Yin
Indolylbutyric acid class, e.g., Etodolac；Sulfonamidess, e.g., nimesulide.
Preferably, optional antiallergic agent includes but is not limited to: Pemirolast Potassiu (
Santen, inc.), Cetirizine Dihydrochloride, levo-cetirizine hydrochloride, and its any prodrug, metabolite,
Derivant, homologue, congener, derivatives, salt, and their compositionss.Anti- malignant cell proliferation
Medicament include but is not limited to, D actinomycin D d, D actinomycin D iv, D actinomycin D i1, D actinomycin D
X1, D actinomycin D c1, dactinomycin (merck &co.,inc.).Antiplatelet
Medicine, anticoagulant, antifibrin and antithrombase include but is not limited to, heparin sodium, low-molecular-weight
Heparin, heparinoid, hirudin, argatroban, Forskolin, vapiprost, ring prostatitis element, class
(chemosynthesis resist for ring prostatitis element, glucosan, DPA-Pro-Arg-chloromethane keto hydrochloride
Thrombin), dipyridamole, glycoprotein ii b/iii a platelet membrane receptor antagonist antibody, restructuring Hirudo
Element, thrombin inhibitor (Biogen, inc.), and any medicine precursor, metabolite,
Derivant, homologue, congener, derivatives, salt and their compositionss.
Preferably, optional hemorrhage generally includes hemocoagulase, Desmopressin, vitamin k 1, dimension life
Plain k3, vitamin k 4, Diaceturate Ethylenediamine, carbazochrome, carbazochrome sodium sulfonate, aminocaproic acid, ammonia
Toluic acid, tranexamic acid, aprotinin, human fibrinogen, thrombin, rutosids, pituitrin.
The powder of available Chinese medicine or injection medical material include, Pseudobulbus Bletillae (Rhizoma Bletillae), Crinis Carbonisatus, Herba Agrimoniae, Radix Notoginseng, Cacumen Platycladi,
Folium Artemisiae Argyi, Radix Sanguisorbae, Flos Sophorae, Radix Cirsii Japonici, Herba Cirsii, Rhizoma Imperatae, Folium Callicarpae Formosanae, Radix Rubiae etc.；Chinese medicine compound has ten
Ash dissipates, Zhixue shengji powder, YUNNAN BAIYAO etc..
Preferably, optional anti-infective generally includes antibacterial, antifungal, antiparasitic, resists
Viral agent, preservative.
The antibacterial that can be used for the present invention includes but is not limited to: aminoglycoside, amphenicols, peace
Arenomycin class, beta-lactam antibiotic, such as penicillins, lincomycin class, Macrolide,
Itrofurans, quinolones class, sulfonamidess, sulfone class, Tetracyclines, vancomycin, and
Their derivant and compositionss.The type agents that can be used for the support of the application include but not office
Be limited to: Amdinocillin, pivmecillinam, amoxicillin, ampicillin, aspoxicillin,
Azidocillin, bacampicillin, benzyl penicillinic acid, penicillin sodium, carbenicillin, carindacillin, chloromethane
XiLin, cloxacillin, ciclacillin, dicloxacillin, epicillin, fenbenicillin, flucloxacillin,
Hetacillin, lenampicillin, metampicillin, Staphcillin sodium, mezlocillin, sodium nafcillin,
Oxazacillin, penamecillin, penethacillin hydriodate, benethamine penicillin, benzathine benzylpenicillin g, green grass or young crops
Mycin g .alpha.-aminodiphenylmethane. salt, penicillin g calcium, Hydrabeamine Penicillin g, penicillin g potassium, procaine
Penicillin g, penicillin n, penicillin o, penicillin v, benzathine benzylpenicillin v, Hydrabeamine Penicillin
That west of v, penimepicycline, penicillin-152, piperacillin, pivampicillin, propicillin, quinoline
Woods, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin.
The antifungal that can be used for the present invention includes but is not limited to: propylamine, imidazoles, polyenoid
Class, Thiocarbamates, triazole type, and its derivative medicament.Antiparasitic includes but does not limit to
In, atovaquone, clindamycin, dapsone, double electricity quinoline, metronidazole, pentamidine, primaquine,
Pyrimethamine, sulfadiazine, trimethoprim/sulfamethoxazole, trimetrexate and its mixture.
The antiviral agent that can be used for the present invention includes but is not limited to: acyclovir, famciclovir, send out
VCV, edoxudine, ganciclovir, FOSCARNET, cidofovir, Fomivirsen, hpmpa (9-
(3- hydroxyl -2- phosphate methoxy propyl group)-adenine), pmea (9- (2- phosphate methoxy propyl group) -
Adenine), hpmpg (9- (3- hydroxyl -2- phosphate methoxy propyl group)-guanine), pmeg (9- [2-
Phosphate methoxy propyl group] guanine), hpmpc (1- (2- phosphate methoxy -3- hydroxypropyl)-cytosine),
Ribavirin, eicar (5- acetenyl -1- β-d- ribofuranosyl -1h- imidazoles -4- Methanamide), pyrrole
Azoles furan rhzomorph (3- [β-d- ribofuranose] -4- hydroxypyrazoles -5- Methanamide), look into 3- Chinese holly woods,
Gr-92938x (1- β-d- ribofuranosyl -1h- pyrazoles -3,4- diformamide), ly253963 (1,3,4-
Thiadiazoles -2- base-cyanamide), rd3-0028 (1,4- dihydro -2,3- benzyl two sulfur), cl387626 (4,4'-
Two [4,6-d] [3- aminobenzene-n, n- bis- (2- carbamoylethyl)-sulfonic acid acid imide] -1,3,5- triazine -2- base ammonia
Base-biphenyl -2-, 2'- sodium disulfonate), babim (two [5- amidino groups -2- benzimidazole-l]-methane) nih351,
And its mixture.
The preservative that can be used for the present invention includes but is not limited to: ethanol, hibitane, iodine tincture, trichlorine
Life, hexachlorophene and silver-based agents: such as silver chloride, silver oxide, nano-Ag particles.
Preferably, optional cytostatics and anti-cell proliferation include but is not limited to: angiopeptin；
Angiotensin converting enzyme inhibitor, such as Captopril (
Bristol-myers squibb co.), cilazapril, lisinopril (
merck&co.,inc.)；Calcium channel blocker, such as nifedipine, Colchicine；Fibroblast gives birth to
The long factor (fgf) antagonist, cod-liver oil (omega-fatty acid)；Histamine antagonist；Lovastatin
(merck &co.,inc.)；Monoclonal antibody, including but not limited to, platelet
Derivative growth factor (pdgf) receptor specific antibody；Sodium nitroprusside；Phosphodiesterase inhibitor；Prostatitis
Parathyrine inhibitor；Suramin；Serotonin blocker；Steroid；Thio protease inhibitor；Platelet
Derivative growth factor (pdgf) antagonist, including but not limited to, triazolo pyrimidine；Nitric oxide；
And its any prodrug, metabolite, derivant, homologue, congener, derivatives, salt, and he
Compositionss.
Preferably, optional chemotherapy and antineoplastic agent include but is not limited to: anticancer agent (e.g., tumor
Chemotherapeutic, biological response modifiers, angiogenesis inhibitor, hormone receptor blocker, low temperature therapy examination
Agent and other can destroy or suppress tumor generate and growth medicament), for example, alkylating agent or its
He can be attacked by dna directly kill cancerous cell medicament (e.g., cycli phosphate amine, isoendoxan),
Nitroso ureas or other pass through to suppress cell dna to repair to kill medicament (e.g., the carmustine of cancerous cell
(bcnu), lomustine (ccnu)), antimetabolite or other pass through disturb specific cells function
Stop the medicament of growth of cancer cells, usually dna synthesis (e.g., 6- mercaptopurine, 5 fluorodioxy pyridines
(5fu), antitumor antibiotics and other can constrain or arrange dna go forward side by side once stop dna close
Become compound (e.g., amycin, daunomycin, epirubicin, idarubicin, mitomycin-c,
Bleomycin A5), plant (Herba Catharanthi Rosei) alkaloid and other by plant extract anti-tumor agent comprising salmosin (e.g.,
Vincristine, vincaleucoblastine), steroid hormone, hormone inhibitors, hormone receptor antagonists and other
Medicament (e.g., tamoxifen, Herceptin, the aromatase suppression that hormone reacts growth of cancers can be affected
Agent, e.g., the different dormancy of amino can and Formestane, triazole inhibitor, e.g., letrozole and Anastrozole, solid
Alcohols inhibitor, e.g., exemestane), anti-angiogenesis albumen, small molecule, gene therapy and (or)
Other can suppress neonate tumour blood vessel or angiopoietic medicament (e.g., meth-1, meth-2, Sa Li
Polyamines), bevacizumab (Avastin), fish shark amine, endostatin, angiostatin, angiozyme,
Ae-941 (neovastat), cc-5013 (revimid, a kind of thalidomide derivatives), medi-522
(vitaxin), 2ME2 (2me2, panzem), CAI (cai), Kang Pu
Auspicious fourth a4 medicine precursor (ca4p), su6668, su11248, bms-275291, col-3, emd
121974th, imc-1c11, im862, tnp-470, Celecoxib (celecoxib celebrex), Rofe
Former times cloth (Vioxx vioxx), interferon-ALPHA, interleukin 12 (il-12) or any in science vol.
Page 289,1197-1201 (aug.17,2000) identified compound, these compounds are all by quoting
It is herein incorporated.Biological effect adjust reagent (e.g., interferon, bacill calmette-guerin (bcg), monoclonal antibody,
Interleukin-22, granulocyte colony-stimulating factor (gcsf) etc.), pgdf receptor antagonist, Herceptin,
Asparaginase, busulfan, carboplatin, cisplatin, carmustine, chlorambucil, cytosine arabinoside, reach
Carbazine, etoposide, flucarbazonesodium, fluorouracil, gemcitabine, hydroxyurea, ifosfamide,
Irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, thioguanine, phosphinothioylidynetrisaziridine,
Raltitrexed, topotecan, bent fourth sulphur ester, vincaleucoblastine, vincristine, mitoazitrone, sand difficult to understand
Sharp platinum, procarbazine, streptostacin, paclitaxel, docetaxel, imuran, docetaxel spread out
Biological homologue, derivatives of these compounds and combinations thereof.
Drug stent in above-described embodiment can be formed by artificial or machine braided silk or tow；?
Can be printed by material 3d and be formed；Can also be formed by cut.
During forming drug stent, thermal finalization and cooling step may be experienced, thus medicine is propped up
Frame is fixed into target shape.Metal material support, whether passes through establishment and shapes or by printing or swashing
Light cutting forming, support is respectively provided with enough support forces, but is in order at uniformity and considers, sometimes needs into one
Step can take the technique quenching and then being tempered to process, and with support bracket fastened shape, reduces stent wires
Or the internal stress within tow, the performance of balancing material.Different from metal material, polymeric material is universal
Matter is soft, and rigidity is not enough, and the shape stability using silk thread or the drug stent of tow knitting forming is poor,
Accordingly, it would be desirable to thermal finalization is carrying out further patterning process.Heat setting temperature chosen material vitrification point
(tg) temperature on, under fusing point (tm).In thermal finalization, need to monofilament or tow
Apply tension force and carry out nervous thermal finalization it is generally the case that fixed length thermal finalization can be taken or determines tension force heat calmly
One of type two ways is operated.3d prints polymer support because of device characteristics reason, the product of making
Major part has isotropic feature, is sometimes also required to carry out thermal finalization to printed polymer support
Reprocessing, the mode that uniaxial tension is usually taken is carried out, to obtain anisotropic feature.Certainly, Gu
Reserve each to different conditions, take multi-shaft stretching equally can also obtain respectively on support simultaneously or asynchronously
Heterotropic effect.After thermal finalization, take quenching mode that support is cooled to room temperature, typically will prop up
It is placed in cold air atmosphere and carries out the temperature process that plunges, cold air ambient temperature should be at vitrification point (tg)
Under, thus make obtaining subject polymer drug stent.
Self-locking can be provided with the silk thread of formation network of the drug stent in above-described embodiment or tow
Point, thus provide the support further enhancing and stable shape for drug stent.
The first implementation of latching point is as shown in figure 8, have a u on the first silk thread or tow 71
Shape groove 711, and the 2nd u shape groove 721 is had on the second silk thread or tow 72, a u shape groove 711
Form latching point 7 with the 2nd u shape groove 721 loose fit, so that the first silk thread or tow 71 and second
Silk thread or tow 72 mutually limit, the fortune between the first silk thread or tow 71 and the second silk thread or tow 72
Dynamic degree of freedom reduces, thus reach strengthening the purpose supporting with solid shape.
The second implementation of latching point is as shown in figure 9, have a u on the first silk thread or tow 81
Shape groove 811, and the 2nd u shape groove 821 is had on the second silk thread or tow 82, a u shape groove 811
Form latching point 8 with the 2nd u shape groove 821 tight fit, so that the first silk thread or tow 81 and second
Silk thread or tow 82 mutually limit, the fortune between the first silk thread or tow 81 and the second silk thread or tow 82
Dynamic degree of freedom reduces, thus reach strengthening the purpose supporting with solid shape.Under normal circumstances, this from
Lock point is irreversible, latching point once after formation, the first silk thread or tow 81 and the second silk thread or tow
82 shapes in this position are relatively fixed it is impossible to produce sliding easily again.
Under normal circumstances, the drug stent of braiding, such as drug stent 1- drug stent 4, have preferably
Elasticity, possesses the conformable of complicated rugged surface, can more preferable adaptation diversity wound surface.But nose sometimes
Chamber support is not to only need to fit to wound surface just to reach using effect, may also need to strong
Support.For example, do not pass through surgical operation, and during directly using support, support certainly will be needed to possess effectively
Support to open nasal meatus to squeeze the pathological changes such as vesicle, or even directly open nasal sinuses mouth.The support of braided support
Property and shape recovery affected by Weaving pattern larger, really, by increasing monofilament line footpath or count
Support performance can be increased, but conveying capacity can be reduced simultaneously, dense braiding can make support become to be difficult to
Enter nasal cavity.Therefore, in order to increase the supportive of braided support, support recovery upon discharge is made to the greatest extent may be used
Can level off to design shape, in braiding artificial above-mentioned latching point can be set.Support release is supportted
In open procedure, self-locking is triggered with operation tool flip stand figure by patient, reaches stable shaped, improve
The effect supporting.Latching point can be arranged on the cross point of silk thread or tow it is also possible to be arranged on non-crossing
Point.Position according to latching point setting and how many, can specify that the relative profile after support release and size.
In other words, by arranging multiple u shape grooves in the precalculated position of silk thread or tow, patient can be according to need
Want flip stand so that two u shape grooves are coordinated, so that support presents the structure that patient wants
Shape is it is also possible in the case of shape is metastable, untiing or adjust self-locking position.So although medicine
Thing support has identical design and weaving manner in an initial condition, but has an effect in diverse location
Latching point the support force of drug stent is adjusted, thus being advantageously implemented the special fixed of nasal cavity support
System.In actual mechanical process, u shape groove can be and new with sliding, separately under the conditions of suitable external force
U shape groove form new latching point, realize the editability of support shape.
In a word, latching point design can specifically adjust as needed.Under normal circumstances, at least 3 from
Lock point is realized relatively stable on three dimensional structure.Except u shape groove above-mentioned, latching point can pass through
Change silk thread or the shape of tow forms the structures such as hole, hole, curved, thorn to realize.
Drug stent in above-described embodiment can equipped with brace rod, Figure 10 give according to the present invention can
The schematic diagram of the brace rod of degraded slow releasing pharmaceutical support.This brace rod 9 can add in Stent,
The degradable silk thread of network will be formed or degradable tow is woven in operation at one with brace rod 9
Form one it is also possible to again by brace rod 9 interpenetration network structure after weave network, together
When do not destroy or change the profile of Metal pylon itself.In the conveying of the drug stent of the present invention with discharged
Cheng Zhong, this brace rod 9 and body and bottom exist as an entirety, after support release, this support
Muscle 9 is released in recess and the profile of bottom of fitting as individual components, in order to open support further.
The concrete shape of this brace rod 9 is not necessarily as shown in Figure 10, in fact, this brace rod is according to drug stent
Wall configuration is changed, and stent returns to be conducive to fit in the profile of bottom to the shape of design,
For example, the bottom surface of elliptic cross-section is adapted to the brace rod of elliptic cross-section.Simplest brace rod is probably
A piece cambered surface bar, complicated brace rod similar to the inside in drug stent recline another same type
Frame.This brace rod 9 can be made up of degradable polymer it is also possible to be made up of metalwork.When brace rod 9
During for metalwork, this brace rod can take out in the later stage of drug stent degraded.The brace rod of metalwork
Advantage is that processing technique is ripe, and conveying is convenient and is provided that higher support force.In fact, it is existing
Drug stent typically each cannot provide sufficiently strong power to extrude vesicle and remain unimpeded all the time in nasal cavity,
The present invention is extruded so as to be retreated by means of the strength of brace rod to vesicle, then under medicine effect
Disappear, thus being directly used in non-endoscopy nasal surgery patient.
Although latching point 8 above-mentioned and brace rod 9 are carried out for braiding operation, should
This understanding, is printed in the drug stent being formed with cut by 3d and can also introduce this mechanism.Grind
Study carefully discovery, 3d printing and the drug stent being laser-cut into are logical in the case of not having brace rod to assist to support
Often also it is provided that good support effect, for the beaded support providing in particular for above-described embodiment 5.
In that case, even if not having brace rod, this drug stent can also be directly used in and peep without intranasal
Mirror nasal surgery patient.
Above-described, only presently preferred embodiments of the present invention, it is not limited to the scope of the present invention,
The above embodiment of the present invention can also make a variety of changes.I.e. every right according to the present patent application will
Seek book and simple, equivalence changes that description is made and modification, fall within the right of patent of the present invention
Claimed scope.The not detailed description of the present invention be routine techniquess content.
Claims (14)
1. a kind of slow releasing pharmaceutical support for nasal cavity, forms grid including being interlaced with one another by silk thread or tow
The main body of structure, described main body is circumferentially extending and has end relative to each other it is characterised in that described
Slow releasing pharmaceutical support also includes being interlaced with one another by silk thread or tow and forms at least one bottom of network,
Outwardly, the periphery of described bottom is engaged described bottom curved with the justified margin of described end, institute
State main body and carry can be by slow release for treating the medicine of sinusitis for described bottom.
2. slow releasing pharmaceutical support according to claim 1 is it is characterised in that described main body has certainly
Lock point, described latching point is the u shape groove being arranged at silk thread or tow being fitted to each other.
3. slow releasing pharmaceutical support according to claim 1 is it is characterised in that described drug stent
The material of silk thread or tow is non-degradable metal, or degradable metal, or non-degradable polymer, or
Degradable polymer, or the mixture of above-mentioned material.
4. slow releasing pharmaceutical support according to claim 1 is it is characterised in that described slow releasing pharmaceutical props up
Frame also includes the brace rod fitting in base profile.
5. slow releasing pharmaceutical support according to claim 4 is it is characterised in that the material of described brace rod
Material is non-degradable metal, or degradable metal, or non-degradable polymer, or degradable polymer,
Or the mixture of above-mentioned material.
6. slow releasing pharmaceutical support according to claim 1 is it is characterised in that described network bag
Triangular grid structures are included.
7. slow releasing pharmaceutical support according to claim 1 is it is characterised in that described medicine is included in
The inside of the material of silk thread or tow, and/or it is coated in the outer surface of the material of silk thread or tow, and/or hold
It is loaded in the network between silk thread or tow.
8. slow releasing pharmaceutical support according to claim 1 is it is characterised in that described drug stent
It is filled with hemostatic material in spill.
9. slow releasing pharmaceutical support according to claim 8 is it is characterised in that described hemostatic material has
There is hygroscopicity and from swollen rising property, thus slow releasing pharmaceutical support described in assisting in opening.
10. slow releasing pharmaceutical support according to claim 8 is it is characterised in that described hemostatic material
It is degradable polymer.
A kind of 11. slow releasing pharmaceutical supports for nasal cavity according to any one of claim 1-10
Forming method it is characterised in that described slow releasing pharmaceutical support passes through artificial or machine braided silk or tow,
Or printed by material 3d, or formed by laser-cut material.
12. forming methods according to claim 11 are it is characterised in that described slow releasing pharmaceutical support
Through thermal finalization and cooling step, thus forming target shape.
13. forming methods according to claim 12 are it is characterised in that described heat setting temperature is situated between
Between material glass temperature and fusing point；Described chilling temperature is less than material glass temperature.
14. forming methods according to claim 11 are it is characterised in that described slow releasing pharmaceutical support
The step manually adjusting through patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510413080.8A CN106344232B (en) | 2015-07-14 | 2015-07-14 | Sustained-release drug stent for nasal cavity and forming method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510413080.8A CN106344232B (en) | 2015-07-14 | 2015-07-14 | Sustained-release drug stent for nasal cavity and forming method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106344232A true CN106344232A (en) | 2017-01-25 |
| CN106344232B CN106344232B (en) | 2022-04-01 |
Family
ID=57842315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510413080.8A Active CN106344232B (en) | 2015-07-14 | 2015-07-14 | Sustained-release drug stent for nasal cavity and forming method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106344232B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913952A (en) * | 2017-02-21 | 2017-07-04 | 东华大学 | A kind of single thread medical multifunctional nasal obstruction and preparation method thereof |
| CN109045447A (en) * | 2018-06-27 | 2018-12-21 | 佛山市蓝瑞欧特信息服务有限公司 | A kind of nasal cavity wound-protecting film with anti-inflammatory anti-itch |
| CN112423739A (en) * | 2018-05-16 | 2021-02-26 | 斯贝洛克斯公司 | Drug delivery implant for allergic rhinitis |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512271A (en) * | 2011-11-18 | 2012-06-27 | 秦永文 | Transcatheter implantation controllable aortic valvular stent |
| CN102988122A (en) * | 2012-11-13 | 2013-03-27 | 浦易（上海）生物技术有限公司 | Prosthetic system for treating nasosinusitis or allergic rhinitis |
| CN103384507A (en) * | 2011-02-09 | 2013-11-06 | 克劳斯·迪林 | Bracket for clamping plate type fixing nasal cavity channel |
| CN104224412A (en) * | 2014-08-20 | 2014-12-24 | 湖南英捷高科技有限责任公司 | Method for preparing intravascular stent upon 3D (three-dimensional) printing technology |
| CN104507419A (en) * | 2012-06-07 | 2015-04-08 | 波士顿科学国际有限公司 | Apparatus for replacing a native heart valve |
| CN204951924U (en) * | 2015-07-14 | 2016-01-13 | 浦易（上海）生物技术有限公司 | A slowly -releasing medicine support for nasal cavity |
-
2015
- 2015-07-14 CN CN201510413080.8A patent/CN106344232B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103384507A (en) * | 2011-02-09 | 2013-11-06 | 克劳斯·迪林 | Bracket for clamping plate type fixing nasal cavity channel |
| CN102512271A (en) * | 2011-11-18 | 2012-06-27 | 秦永文 | Transcatheter implantation controllable aortic valvular stent |
| CN104507419A (en) * | 2012-06-07 | 2015-04-08 | 波士顿科学国际有限公司 | Apparatus for replacing a native heart valve |
| CN102988122A (en) * | 2012-11-13 | 2013-03-27 | 浦易（上海）生物技术有限公司 | Prosthetic system for treating nasosinusitis or allergic rhinitis |
| CN104224412A (en) * | 2014-08-20 | 2014-12-24 | 湖南英捷高科技有限责任公司 | Method for preparing intravascular stent upon 3D (three-dimensional) printing technology |
| CN204951924U (en) * | 2015-07-14 | 2016-01-13 | 浦易（上海）生物技术有限公司 | A slowly -releasing medicine support for nasal cavity |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913952A (en) * | 2017-02-21 | 2017-07-04 | 东华大学 | A kind of single thread medical multifunctional nasal obstruction and preparation method thereof |
| CN112423739A (en) * | 2018-05-16 | 2021-02-26 | 斯贝洛克斯公司 | Drug delivery implant for allergic rhinitis |
| CN109045447A (en) * | 2018-06-27 | 2018-12-21 | 佛山市蓝瑞欧特信息服务有限公司 | A kind of nasal cavity wound-protecting film with anti-inflammatory anti-itch |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106344232B (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988122B (en) | Prosthetic system for treating nasosinusitis or allergic rhinitis | |
| US20230046852A1 (en) | Expandable devices and methods therefor | |
| US20210378698A1 (en) | Device and methods for treating paranasal sinus conditions | |
| CN106137482B (en) | A kind of nasal sinus stent and transport system | |
| CN204951924U (en) | A slowly -releasing medicine support for nasal cavity | |
| CN106344232A (en) | Sustained release medicine bracket for nasal cavity, forming method and application thereof | |
| CN204766053U (en) | Nasal sinus support and conveying system | |
| AU2015201043B2 (en) | Expandable devices and methods therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 2206, No. 396, lishizhen Road, Pudong New Area, Shanghai 201203 Applicant after: Puyi (Shanghai) Biotechnology Co.,Ltd. Address before: Room 2206, No. 396, lishizhen Road, Pudong New Area, Shanghai 201203 Applicant before: PUYI (SHANGHAI) BIOTECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |